Double-dose firmonertinib as first-line treatment in patients with locally advanced or metastatic non-small-cell lung cancer harboring EGFR L858R mutation: a prospective, multicenter, phase II study (FIRM)
- Bo Shen
- Chun Wang
- Liqin Zhang
- Yingying Zhu
- Xing Zhang
- Xiaoxuan Wang
- Zhen Guo
- Li Wang
- Xiaohua Wang
- Liqun Zhu
- Yun Zhou
- Danting Liao
- Meiqi Shi
2026-01-19